Gossamer Bio, Inc. (GOSS): History, Ownership, Mission, How It Works & Makes Money

Ever heard of Gossamer Bio, Inc. (GOSS) and wondered what they're all about? This late-stage clinical biopharmaceutical company is making waves with its focus on developing treatments for pulmonary hypertension, but what's their story, and how do they operate? With their lead drug candidate, seralutinib, advancing through Phase 3 trials and a solid $294.5 million in cash reserves at the end of 2024, discover how they plan to reshape the treatment landscape for this challenging condition.

Gossamer Bio, Inc. (GOSS) History

Gossamer Bio's Founding Timeline

Year established

The company was established in 2017.

Original location

The company is headquartered in San Diego, California.

Founding team members

The founding team included:

• Sheila Gujrathi, MD
• Faheem Hasnain
• Bryan Giraudo

Initial capital/funding

In 2018, the company completed a Series A financing round, raising $100 million. This was followed by a Series B financing round in 2018, securing an additional $230 million.

Gossamer Bio's Evolution Milestones

Gossamer Bio's Transformative Moments

• Strategic Pipeline Expansion: The in-licensing of GB001 (seralutinib) marked a pivotal moment, providing a late-stage clinical asset that addressed a significant unmet medical need in pulmonary arterial hypertension.
• Successful IPO: The 2019 IPO was transformative, providing the financial resources necessary to advance multiple clinical programs simultaneously. The $276.1 million raised allowed for significant investment in research and development.
• Clinical Trial Diversification: Initiating Phase 2 trials for GB002 and advancing GB127 into clinical development broadened the company's therapeutic focus and reduced reliance on a single asset.
• Navigating Clinical Trial Outcomes: The topline results from the TORRANCE study in 2022 represented a critical juncture, requiring strategic reassessment and potential adjustments to the company's development priorities.

For insights into the company's guiding principles, explore Mission Statement, Vision, & Core Values of Gossamer Bio, Inc. (GOSS).

Gossamer Bio, Inc. (GOSS) Ownership Structure

Gossamer Bio, Inc. features a mixed ownership structure, encompassing institutional investors, individual shareholders, and company insiders.

Gossamer Bio, Inc. Current Status

As of November 10, 2023, Gossamer Bio, Inc. is a publicly traded company. This means that shares of the company are available for purchase by the general public on a stock exchange.

Gossamer Bio, Inc. Ownership Breakdown

The ownership of Gossamer Bio, Inc. is distributed among various shareholders, including institutional investors, individual shareholders, and potentially company insiders. As of the fiscal year 2024, the estimated ownership breakdown is as follows:

Gossamer Bio, Inc. Leadership

The leadership team at Gossamer Bio, Inc. plays a crucial role in guiding the company's strategic direction and operations. Key members of the leadership team include:

• Faheem Hasnain: Chairman of the Board
• Sheila Gujrathi, MD: President and Chief Executive Officer
• Bryan Giraudo: Chief Financial Officer

For more detailed insights into Gossamer Bio's investor profile, you might find this resource helpful: Exploring Gossamer Bio, Inc. (GOSS) Investor Profile: Who’s Buying and Why?

Gossamer Bio, Inc. (GOSS) Mission and Values

Gossamer Bio strives to address significant unmet needs in the medical field, focusing on immunology, inflammation, and oncology. The company is driven by a commitment to scientific innovation and improving patient outcomes.

Gossamer Bio's Core Purpose

Official mission statement

Gossamer Bio's mission statement is not explicitly available in the provided search results. However, based on the company's activities and focus areas, it can be inferred that their mission revolves around:

• Developing and commercializing novel therapies for patients suffering from immunological, inflammatory, and oncological diseases.
• Advancing scientific understanding in these therapeutic areas to create innovative treatment options.
• Improving the quality of life for patients by addressing unmet medical needs with targeted and effective solutions.

Vision statement

Similarly, a specific vision statement for Gossamer Bio is not found in the search results. Nevertheless, their vision can be understood as:

• Becoming a leading biopharmaceutical company recognized for its contributions to immunology, inflammation, and oncology.
• Pioneering new treatment paradigms through cutting-edge research and development.
• Delivering significant value to patients, healthcare providers, and shareholders by transforming scientific discoveries into impactful medicines.

Company slogan/tagline

There is no readily available information regarding Gossamer Bio's official slogan or tagline in the provided search results. For more in-depth information about the company's mission, vision, and values, you can explore: Mission Statement, Vision, & Core Values of Gossamer Bio, Inc. (GOSS).

Gossamer Bio, Inc. (GOSS) How It Works

Gossamer Bio, Inc. is a biopharmaceutical company that focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology.

Gossamer Bio, Inc.'s Product/Service Portfolio

Gossamer Bio, Inc.'s Operational Framework

Gossamer Bio operates through a focused approach to drug development, concentrating on specific therapeutic areas with unmet medical needs. Their operational framework includes:

• Target Identification and Acquisition: Identifying promising drug candidates or technologies through internal research or acquisition.
• Clinical Development: Conducting rigorous preclinical and clinical trials to evaluate the safety and efficacy of their drug candidates. This involves multiple phases (Phase 1, Phase 2, Phase 3) to ensure the drug meets regulatory standards and demonstrates therapeutic benefits.
• Regulatory Approval: Seeking approval from regulatory bodies such as the FDA (in the United States) to market and sell their drugs.
• Commercialization: If a drug receives regulatory approval, Gossamer Bio would then focus on manufacturing, marketing, and distributing the drug to healthcare providers and patients.

For more insights into Gossamer Bio, Inc.'s financial standing, consider exploring this resource: Breaking Down Gossamer Bio, Inc. (GOSS) Financial Health: Key Insights for Investors

Gossamer Bio, Inc.'s Strategic Advantages

Gossamer Bio's strategic advantages may include:

• Focused Therapeutic Areas: By concentrating on immunology, inflammation, and oncology, Gossamer Bio can develop specialized expertise and potentially achieve a higher success rate in these areas.
• Innovative Drug Candidates: A portfolio of novel drug candidates targeting validated biological pathways.
• Experienced Management Team: A leadership team with a track record of success in drug development and commercialization.
• Strategic Partnerships: Collaborations with other companies or research institutions to accelerate drug development or expand their product pipeline.

Gossamer Bio, Inc. (GOSS) How It Makes Money

Gossamer Bio, Inc. is a biopharmaceutical company that focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. As of now, the company primarily generates revenue through strategic collaborations and licensing agreements rather than direct product sales, as it is still in the clinical development stage.

Gossamer Bio, Inc.'s Revenue Breakdown

Since Gossamer Bio, Inc. does not currently have products on the market, its revenue streams are primarily derived from collaborative agreements and out-licensing of its intellectual property. The percentages and trends below reflect the importance of these revenue sources to the company’s overall financial status.

Gossamer Bio, Inc.'s Business Economics

Gossamer Bio, Inc.’s business economics are characterized by substantial investment in research and development, typical of a clinical-stage biopharmaceutical company. Key aspects include:

• R&D Expenses: A significant portion of operating expenses is allocated to advancing drug candidates through clinical trials.
• Partnerships: Strategic alliances can provide upfront payments, milestone payments, and royalties on future sales, which offset some R&D costs.
• Cash Burn: The company experiences a high cash burn rate due to intensive research activities and clinical trials. Effective cash management is crucial for sustaining operations until products reach commercialization.
• Intellectual Property: The value of Gossamer Bio, Inc. is heavily reliant on its patent portfolio and the exclusivity it provides for its drug candidates.

Gossamer Bio, Inc.'s Financial Performance

Gossamer Bio, Inc.'s financial performance can be evaluated through several key metrics:

• Revenue: In 2024, Gossamer Bio, Inc. reported total revenues of $15.3 million.
• Net Loss: The company experienced a net loss of $144.2 million for the year ended December 31, 2024, compared to a net loss of $174.2 million for the same period in 2023.
• R&D Expenses: Research and development expenses were $84.4 million for the year ended December 31, 2024, compared to $124.9 million for the same period in 2023.
• Cash Position: As of December 31, 2024, Gossamer Bio, Inc. had cash, cash equivalents, and marketable securities totaling $224.4 million.
• Operating Expenses: Total operating expenses for 2024 were $160.5 million, a decrease from $200.1 million in 2023.

To gain more insights into Gossamer Bio, Inc.'s financial standing, you might find this resource helpful: Breaking Down Gossamer Bio, Inc. (GOSS) Financial Health: Key Insights for Investors

Gossamer Bio, Inc. (GOSS) Market Position & Future Outlook

As of April 2025, Gossamer Bio is navigating a competitive biopharmaceutical landscape, focusing on the development and commercialization of therapeutics in the areas of immunology, inflammation, and oncology. Their future success hinges on the clinical trial outcomes of their key drug candidates and their ability to secure partnerships and funding.

Competitive Landscape

Opportunities & Challenges

Industry Position

Gossamer Bio holds a niche position within the biopharmaceutical industry, characterized by its focus on specific therapeutic areas and innovative drug development programs.

• Pipeline Focus: Specializing in immunology, inflammation, and oncology provides a targeted approach.
• R&D Investment: Continued investment in research and development is crucial for sustained competitiveness.
• Market Access: Successfully navigating regulatory pathways and securing market access are vital for commercial success.

For more insights into the financial aspects, check out: Breaking Down Gossamer Bio, Inc. (GOSS) Financial Health: Key Insights for Investors